Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 3Expanded_access 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Recurrence 2Multiple Myeloma 2

Interventions

3-Iodobenzylguanidine 3talquetamab 2ibrutinib 2zanubrutinib 1vorasidenib 1sugemalimab 1revumenib 1pomalidomide 1loncastuximab tesirine 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Whole-Body Irradiation 1Tacrolimus 1Panobinostat 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Recurrence × talquetamab × Clear all
NCT05503550 2025-12-16

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

No longer available
Plasma cell

Multiple Myeloma, Recurrence

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Approved for marketing
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡